- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05619939
Impact of Protein Source on Gut Health
April 18, 2024 updated by: David Montrose, Stony Brook University
Determining the Effect of Dietary Protein Source on Intestinal Health
The gastrointestinal (GI) tract is a central hub for human health given its essential role in nutrient absorption, waste production and immunity.
Diet is a major contributor to gut health including affecting the incidence and severity of GI disease.
This is mediated, at least in part, by the presence of microbiota, a highly diet-dependent biome.
In fact, dietary changes are capable of altering bacterial populations and/or microbial metabolism, which in turn, controls the type and abundance of small molecules being produced in the gut, many of which can exert biological effects.
Several lines of evidence suggest that dietary protein in particular, can impact gut health.
Therefore, this trial will test whether dietary protein type differentially impacts gut function in humans by carrying out a single-blinded randomized cross-over controlled feeding study in healthy individuals.
Subjects will be provided with an individualized very low protein diet augmented with pea- or egg white-derived protein supplements, as their major protein source.
The impact of consuming pea vs. egg white protein on 1) the fecal metabolome, 2) gut barrier function and 3) gastrointestinal symptoms will be determined.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794
- Stony Brook University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 30 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- BMI of 18-29.9
Exclusion Criteria:
- Those with a history of significant illness including diabetes, renal, liver or cardiovascular disease, malnutrition, GI disease (including IBS, IBD, chronic constipation or diarrhea), mental illness (i.e. depression, bipolar disorder)
- Those adhering to a vegan diet or vegetarian diet exclusive of eggs
- Those having taken probiotics or antibiotics within 1 month of starting the study
- Those who are pregnant or plan to become pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pea protein to egg white protein
This arm will receive 10 days of pea protein isolate followed by 10 days of consuming egg white protein isolate, with the two treatment periods separated by a 14-day washout period.
|
The indicated protein isolates will be given to subjects as their major protein source
|
|
Experimental: Egg white protein to pea protein
This arm will receive 10 days of egg white protein isolate followed by 10 days of consuming pea protein isolate, with the two treatment periods separated by a 14-day washout period.
|
The indicated protein isolates will be given to subjects as their major protein source
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fecal metabolome
Time Frame: This analysis will be carried out at baseline and the end of each treatment period, entailing 4 measurements over an approximately 36 day period
|
Mass-spectrometry based analysis of the relative abundance of metabolites will be carried out on feces.
|
This analysis will be carried out at baseline and the end of each treatment period, entailing 4 measurements over an approximately 36 day period
|
|
Intestinal permeability
Time Frame: This analysis will be carried out at baseline and the end of each treatment period, entailing 4 measurements over an approximately 36 day period
|
Subjects will undergo lactulose-mannitol test to inform on gut permeability
|
This analysis will be carried out at baseline and the end of each treatment period, entailing 4 measurements over an approximately 36 day period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence to study diets
Time Frame: Daily over two, 10-day periods
|
consumption of study diets will be recorded through subject-reported surveys before and after eating.
|
Daily over two, 10-day periods
|
|
Amount of study diets consumed
Time Frame: Daily over two, 10-day periods
|
Subjects will take pictures of food items before and after eating to assess the amount of each study diet item consumed.
|
Daily over two, 10-day periods
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: David C Montrose, PhD, Stony Brook University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 18, 2023
Primary Completion (Actual)
April 28, 2023
Study Completion (Actual)
April 28, 2023
Study Registration Dates
First Submitted
November 9, 2022
First Submitted That Met QC Criteria
November 9, 2022
First Posted (Actual)
November 17, 2022
Study Record Updates
Last Update Posted (Actual)
April 19, 2024
Last Update Submitted That Met QC Criteria
April 18, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- 2022-00427
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diet, Healthy
-
University of ReadingCompletedDiet Modification | Diet, Healthy | Diet HabitUnited Kingdom
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruitingDiet, Healthy | Diet Habit | Nutrition, Healthy | Dietary ExposureMexico
-
University of ManitobaRecruitingHealthy | Healthy DietCanada
-
Washington State UniversityUnited States Department of Agriculture (USDA)CompletedHealth Behavior | Diet, Healthy | Diet HabitUnited States
-
Mälardalen UniversitySwedish Environmental Research Institute (IVL)Active, not recruitingHealthy Diet | Healthy LifestyleSweden
-
Green Chef CorporationCitruslabsCompletedHealthy Diet | Healthy NutritionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Luis María Béjar PradoRecruitingHealthy Eating Index | Mediterranean Diet | Diet HabitsSpain
-
Oregon State UniversityNot yet recruiting
-
University of HawaiiPennington Biomedical Research Center; United States Department of Agriculture...RecruitingDiet, HealthyUnited States
Clinical Trials on Protein isolate
-
University of WestminsterCoventry UniversityCompletedAppetite and General Nutritional DisordersUnited Kingdom
-
University of Missouri-ColumbiaRecruitingGlucose Metabolism Disorders | Metabolic Syndrome | Metabolic Syndrome, Protection AgainstUnited States
-
Instituto Potosino De Investigacion Cientifica...CompletedOverweight and ObesityMexico
-
University of FloridaCompletedRenal Failure | Chronic Kidney Disease Requiring Chronic DialysisUnited States
-
INQUIS Clinical ResearchCompletedPrediabetes | Normoglycemia | Normal Plasma GlucoseCanada
-
Arne AstrupCompletedAppetite; Lack or Loss, Nonorganic OriginDenmark
-
Maastricht University Medical CenterCosunRecruitingCerebral Blood Flow | Cognitive Function | Satiety | Brain Vascular Function | Brain Insulin SensitivityNetherlands
-
Universidad Pablo de OlavideUniversidad Europea de MadridCompletedInsomnia | Sleep Quality | Sleep DisordersSpain
-
Mette HansenAker Biomarine Antarctic ASCompletedHuman NutritionDenmark
-
Daniel MooreLesaffre InternationalRecruiting